

Table of contents

<i>Chapter 1.</i>	Introduction	7
<i>Chapter 2.</i>	Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations	22
<i>Chapter 3.</i>	Risks of cancers other than breast and ovarian cancer in BRCA1 mutation carriers	42
<i>Chapter 4.</i>	Cancer risks in BRCA2 families: estimates for sites other than breast and ovary	58
<i>Chapter 5.</i>	Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study: A report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group	70
<i>Chapter 6.</i>	Hormone replacement therapy and risk of breast cancer in the International BRCA1/2 Carrier Cohort Study (IBCCS)	78
<i>Chapter 7.</i>	General discussion and summary	93
	Section 1: Introduction	94
	Section 2: Main research findings	94
	Section 3: Methodological considerations	96
	Section 4: Results in perspective: what did others find?	103
	Section 5: Clinical implications	108
	Section 6: Future research	110
<i>Chapter 8.</i>	Appendices	118
	Samenvatting	119
	Acknowledgement / Dankwoord	125
	About the author	133
	List of publications	135